checkAd

    GENOMIC VISION  228  0 Kommentare  Promising Results from the New Telomere Length Assay (TLA) in the Scope of Development of Cancer Therapies - Seite 3

    This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions

    Lesen Sie auch


    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    GENOMIC VISION  Promising Results from the New Telomere Length Assay (TLA) in the Scope of Development of Cancer Therapies - Seite 3 Regulatory News: GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome, announced today promising results from its …